Skip to content
April 23, 2024

Equity.Guru

Investment information for the new generation

Search

medical psilocybin

Our Psychedelic Trip Isn’t Over   I don’t know the first thing about psychedelics. Rather, that’s what I would have been saying back in 2020 when the psychedelics sector…
Standardizing Psychedelic-Assisted Therapy $25.537M Market Capitalization Filament Health Corp. (FH.NE) announced today that it has entered into a licensing agreement with ATMA Journey Centers. Under the agreement, Filament has…
A Change In Stance Filament Health Corp (FH.NE) announced today that Psilo Scientific Ltd., the Company’s wholly-owned subsidiary, has joined Health Canada’s list of licensed psilocybin producers. No, we…
$140.123M Market Capitalization Numinus Wellness Inc. (NUMI.T) announced today that it has formally submitted its clinical trial application (CTA) to Health Canada for its Phase 1 study, HOPE, on…
Core One Labs (COOL.C) has completed the acquisition of Akome Biotech, a psychedelic-based pharmaceuticals company focused on providing effective and safe solutions to patients suffering from stroke and neurological…
Cybin (CYBN.NE) is in a prime position as the push for psychedelic medicine surges across North America and around the world. Scientific evidence supports the life-changing impact of medicinal…
Mind Cure Health Inc. has completed its initial strategic equity investment. The investment equates to approximately 13-per-cent ownership in ATMA Journey Centers Inc. in accordance with the terms specified…
Pure Extracts Technologies (PULL.C) commenced a study on the formulation and manufacturing of psilocybin-based treatments today, according to a press release. The products will come as oral tablets, capsules…
Let’s talk for a moment about Measure 109. The measure was a vote on whether or not to allow licensed service providers the ability to https://e4njohordzs.exactdn.com/wp-content/uploads/2021/10/tnw8sVO3j-2.pngister psilocybin producing mushroom…
Normally when we we write about Revive Therapeutics (RVV.C), it’s generally to provide an update on their progress regarding their experimental COVID-19 palliative, Bucillamine. This update isn’t that, and…